Could an arthritis drug save lives in HIV-TB meningitis?

NCT ID NCT05590455

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 16 times

Summary

This study tests whether adding adalimumab (a drug used for arthritis) to standard treatment can reduce deaths in HIV patients with tuberculosis meningitis. About 130 adults in Brazil, Mozambique, and Zambia will receive either adalimumab or placebo alongside anti-TB drugs and steroids. The main goal is to see if this combination lowers the chance of dying within 3 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Adult Infectious Diseases Centre, University Teaching Hospital

    NOT_YET_RECRUITING

    Lusaka, Zambia

    Contact Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • Instituto Nacional de Saude

    NOT_YET_RECRUITING

    Maputo, Mozambique

    Contact

    Contact Email: •••••@•••••

  • Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ

    RECRUITING

    Rio de Janeiro, 21040-900, Brazil

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.